Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of standardized uptake value (SUV) and apparent diffusion coefficient (ADC) as prognostic imaging parameters for primary Ewing sarcoma in hybrid 18F-FDG-PET/MRI.

European journal of radiology·2026
Same author

Diagnostic value of integrated 18F-fluorodeoxyglucose PET/MRI in initial staging and recurrence detection of Ewing sarcoma.

Nuclear medicine communications·2026
Same author

Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial.

The Lancet. Haematology·2026
Same author

Treatment effect heterogeneity of radiotherapy in localized Ewing sarcoma: A secondary analysis of the EURO-E.W.I.N.G. 99 and Ewing 2008 trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Sepsis profile among preterm infants with enterostomy and fecal transfer: a multicenter retrospective cohort study.

Molecular and cellular pediatrics·2026
Same author

Potential biomarkers of Ewing sarcoma identified through a Europe-wide analysis of prospectively collected samples.

Scientific reports·2026
Same journal

Neuromuscular Changes During the Six-Minute Walk Test in Pediatric Sickle Cell Disease.

Pediatric hematology and oncology·2026
Same journal

Early discharge for low-risk pediatric febrile neutropenia: safe only in selected centers.

Pediatric hematology and oncology·2026
Same journal

Clinical and microbiological characteristics of viridans group streptococcal bacteremia in pediatric and adolescent patients with cancer.

Pediatric hematology and oncology·2026
Same journal

Parental and Patients' Awareness, Knowledge, and Willingness for Human Papillomavirus Vaccination Among Survivors of Childhood Hematologic Malignancies.

Pediatric hematology and oncology·2026
Same journal

How we Investigate Bone Marrow Failure Syndromes in Pediatric Patients.

Pediatric hematology and oncology·2026
Same journal

Prepubertal Initiation of Imatinib is Associated with Reduced Final Height in Children with Chronic Myeloid Leukemia.

Pediatric hematology and oncology·2026
See all related articles

Related Experiment Video

Updated: May 25, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Ewing sarcoma: biology-based therapeutic perspectives.

Jenny Potratz1, Heribert Jürgens, Alan Craft

  • 1Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.

Pediatric Hematology and Oncology
|February 7, 2012
PubMed
Summary
This summary is machine-generated.

Ewing sarcoma, a rare childhood cancer, arises from EWS-ETS fusion genes. Understanding its molecular basis is key to developing targeted treatments for this malignancy.

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Related Experiment Videos

Last Updated: May 25, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Area of Science:

  • Pediatric Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Ewing sarcoma is a rare pediatric malignancy.
  • It is characterized by specific chromosomal translocations creating EWS-ETS fusion genes.
  • These aberrant transcription factors are crucial in initiating and maintaining the tumor.

Purpose of the Study:

  • To provide an overview of the biological underpinnings of Ewing sarcoma.
  • To discuss emerging biology-based targeted treatment strategies.

Main Methods:

  • Review of current scientific literature on Ewing sarcoma.
  • Analysis of molecular mechanisms involving EWS-ETS transcription factors.
  • Synthesis of data on potential targeted therapies.

Main Results:

  • EWS-ETS fusion proteins are central to Ewing sarcoma pathogenesis.
  • These factors dysregulate intracellular signaling pathways.
  • Targeted therapies are beginning to emerge based on this molecular understanding.

Conclusions:

  • Ewing sarcoma provides a model for studying cancer development.
  • Targeted treatment strategies are advancing due to a better understanding of its molecular biology.
  • Further research is needed to translate these findings into effective clinical interventions.